Logo

Lundback's Vyepti (eptinezumab- IV) Receives Health Canada's Approval for Preventive Treatment of Migraine

Share this

Lundback's Vyepti (eptinezumab- IV) Receives Health Canada's Approval for Preventive Treatment of Migraine

Shots:

  • The approval follows P-III trials (PROMISE-1 in episodic migraine & PROMISE-2 in chronic migraine) assessing Vyepti vs PBO in 2-076 adult patients for the preventive treatment of migraine who have at least 4 migraine days/mos.
  • The studies met its 1EPs of decrease in mean monthly migraine days (MMD) over 1-12wks and showed 50% & 75% responder rates & good tolerability
  • Vyepti is a humanized mAb that binds to calcitonin gene-related peptide (CGRP)

 ­ Ref: PRNewswire | Image: Lundback

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions